keyword
https://read.qxmd.com/read/38576917/research-progress-on-molecular-mechanism-of-pyroptosis-caused-by-helicobacter-pylori-in-gastric-cancer
#21
REVIEW
Yulan Gu, Yeqiong Xu, Ping Wang, Yu Zhao, Chuandan Wan
Gastric cancer (GC) is a prevalent malignancy worldwide. Helicobacter pylori ( H. pylori ), a Gram-negative spiral bacterium, has the ability to colonize and persist in the human gastric mucosa. Persistent H. pylori infection has been identified as a major risk factor for ~80% of GC cases. The interplay between H. pylori pathogenicity, genetic background, and environmental factors collectively contribute to GC transformation. Eradicating H. pylori infection is beneficial in reducing the recurrence of gastric cancer and residual cancer...
April 2024: Annals of Medicine and Surgery
https://read.qxmd.com/read/38576818/primary-gastroduodenal-tuberculosis-presenting-as-gastric-outlet-obstruction-a-case-report-and-review-of-literature
#22
Abdihamid Mohamed Ali, Yahye Garad Mohamed, Abdirahman Ahmed Mohamud, Abdulkadir Nor Mohamed, Mohamed Rage Ahmed, Ismail Mohamud Abdullahi, Tuba Saydam
BACKGROUND: Mycobacterium tuberculosis (TB) is the causative agent of TB, a chronic granulomatous illness. This disease is prevalent in low-income countries, posing a significant global health challenge. Gastrointestinal TB is one of the three forms. The disease can mimic other intra-abdominal conditions, leading to delayed diagnosis owing to the absence of specific symptoms. While gastric outlet obstruction (GOO) remains a frequent complication, its incidence has declined with the advent of proton pump inhibitors and Helicobacter pylori eradication therapy...
March 16, 2024: World Journal of Clinical Cases
https://read.qxmd.com/read/38572895/continuing-medical-education-questions-april-2024
#23
JOURNAL ARTICLE
Raquel E Davila
Article Title: Effectiveness of Helicobacter pylori treatments according to antibiotic resistance.
April 1, 2024: American Journal of Gastroenterology
https://read.qxmd.com/read/38570412/the-gut-microbiota-in-parkinson-disease-interactions-with-drugs-and-potential-for-therapeutic-applications
#24
JOURNAL ARTICLE
Elisa Menozzi, Anthony H V Schapira
The concept of a 'microbiota-gut-brain axis' has recently emerged as an important player in the pathophysiology of Parkinson disease (PD), not least because of the reciprocal interaction between gut bacteria and medications. The gut microbiota can influence levodopa kinetics, and conversely, drugs administered for PD can influence gut microbiota composition. Through a two-step enzymatic pathway, gut microbes can decarboxylate levodopa to dopamine in the small intestine and then dehydroxylate it to m-tyramine, thus reducing availability...
April 3, 2024: CNS Drugs
https://read.qxmd.com/read/38569609/type-2-diabetes-mellitus-and-helicobacter-pylori-eradication-in-a-clinical-population
#25
JOURNAL ARTICLE
Grace Sekaya, Frances Wang, HannahSofia Brown, Priya Alagesan, Bryan C Batch, Katherine S Garman, Meira Epplein
OBJECTIVES: Eradication of Helicobacter pylori reduces the risk of gastric cancer (GC). Individuals with type 2 diabetes mellitus (T2DM) are known to be at increased risk for GC. In a cohort of H. pylori -positive individuals, we assessed whether those with T2DM were at risk of persistent infection following H. pylori treatment compared with individuals without T2DM. METHODS: A random subset of all individuals diagnosed as having H. pylori without intestinal metaplasia at endoscopy from 2015 to 2019 were stratified evenly by race (Black and White)...
April 2024: Southern Medical Journal
https://read.qxmd.com/read/38559406/a-case-report-of-a-gastric-ulcer-in-a-2-5-month-old-infant-in-syria-helicobacter-pylori-and-aspirin-as-possible-causes
#26
Nafiza Martini, Maha Al Haj Kaddour, Mouna Baddoura, Mulham Jarjanazi, Jaber Mahmoud
A gastric ulcer is a tear in the stomach lining that manifests as abdominal pain, nausea, vomiting, and weight loss. Its occurrence is lesser in children as compared to adults and its incidence in children ranges between 2% and 8%. Helicobacter pylori and nonsteroidal anti-inflammatory drugs are the most common causes of gastric ulcers. In our case, we report a 2.5-month-old male who presented with severe pallor, hematemesis, and melena with normal weight gain. The patient's mother was infected with COVID-19 a month ago and recovered within 5 days but kept using aspirin and nonsteroidal anti-inflammatory drugs for a month during breastfeeding...
2024: SAGE Open Medical Case Reports
https://read.qxmd.com/read/38558931/trif-ifn-i-pathway-in-helicobacter-induced-gastric-cancer-in-an-accelerated-murine-disease-model-and-patient-biopsies
#27
JOURNAL ARTICLE
Prerna Bali, Ivonne Lozano-Pope, Jonathan Hernandez, Monica V Estrada, Maripat Corr, Michael A Turner, Michael Bouvet, Christopher Benner, Marygorret Obonyo
Helicobacter pylori ( H. pylori) infection is a known cause of many digestive diseases, including gastritis, peptic ulcers, and gastric cancer. However, the underlying mechanisms by which H. pylori infection triggers these disorders are still not clearly understood. Gastric cancer is a slow progressing disease, which makes it difficult to study. We have developed an accelerated disease progression mouse model, which leverages mice deficient in the myeloid differentiation primary response 88 gene ( Myd88 -/- ) infected with Helicobacter felis ( H...
April 19, 2024: IScience
https://read.qxmd.com/read/38558539/mucus-and-biofilm-penetrating-nanoplatform-as-an-ultrasound-induced-free-radical-initiator-for-targeted-treatment-of-helicobacter-pylori-infection
#28
JOURNAL ARTICLE
Jinjie Fan, Yuze Dong, Yue Sun, Yalan Ji, Jie Feng, Peijuan Yan, Yingnan Zhu
Helicobacter pylori (H. pylori) infection is closely associated with the development of various gastric diseases. The effectiveness of current clinical antibiotic therapy is hampered by the rise of drug-resistant strains and the formation of H. pylori biofilm. This paper reports a sonodynamic nanocomposite PtCu3 -PDA@AIPH@Fucoidan (PPAF), which consists of dopamine-modified inorganic sonosensitizers PtCu3 , alkyl radicals (R•) generator AIPH and fucoidan, can penetrate the mucus layer, target H. pylori, disrupt biofilms, and exhibit excellent bactericidal ability...
April 1, 2024: Advanced Healthcare Materials
https://read.qxmd.com/read/38557327/safety-profile-of-helicobacter-pylori-eradication-treatments-literature-review-and-updated-data-of-the-european-registry-on-helicobacter-pylori-management-hp-eureg
#29
REVIEW
Irina Luzko, Olga P Nyssen, Leticia Moreira, Javier P Gisbert
INTRODUCTION: Helicobacter pylori (H. pylori), the most prevalent chronic infection globally, is the major cause of relevant diseases such as gastric cancer, leading to high morbidity and mortality worldwide. Several studies have focused on optimize H. pylori eradication treatment through combination therapies and antibiotic resistance. However, the adverse events profile and its impact, as a primary outcome, remains underexplored.The aim of this review was to summarize the available data on the safety of the most common regimens for H...
April 1, 2024: Expert Opinion on Drug Safety
https://read.qxmd.com/read/38554984/helicobacter-pylori-eradication-with-high-dose-proton-pump-inhibitor-amoxicillin-dual-therapy-a-systematic-review-and-meta-analysis
#30
JOURNAL ARTICLE
Jia-Ai Yeh, Huei-Kai Huang, Ai-Li Chou, Hwai-Jeng Lin, Chun-Lung Feng, Chia-Jung Kuo, Chih-Ho Lai
BACKGROUND: Resistance of Helicobacter pylori to many antibiotics, which lowers the efficacy of eradication therapy, is increasingly prevalent. High-dose proton pump inhibitor (PPI)-amoxicillin dual therapy (HDDT) has been used for H. pylori eradication for years, and resistance to amoxicillin is relatively rare. Although many studies have compared the eradication rate of HDDT with that of guideline therapies, the reported efficacy of HDDT varies greatly and is inconsistent. AIMS: This study investigated the eradication rate and adverse effects of HDDT compared with the guidelines at the time of the study...
March 28, 2024: International Journal of Antimicrobial Agents
https://read.qxmd.com/read/38551425/literature-review-analysis-of-the-current-state-of-targeted-therapy-for-gastrointestinal-cancers
#31
JOURNAL ARTICLE
Xinge Miao, Chenxing Jin, Xiang Ji, Yibin Teng, Jiwei Liu
Globally, more than one million new cases of gastric cancer are anticipated by 2024, representing a significant unmet clinical need. It is the fourth most prevalent cancer in men and the seventh most prevalent cancer in women. The pathogens Helicobacter pylori (H. pylori) and Epstein-Barr virus (EBV) have been linked to a significant number of cases of gastric cancer. On the other hand, the recorded results were not particularly impressive because the gastrointestinal tract (GI) is frequently diagnosed at a very advanced stage, traditional treatments are not very effective, and they have several adverse side effects...
March 29, 2024: Alternative Therapies in Health and Medicine
https://read.qxmd.com/read/38550410/unveiling-a-coalescing-catastrophe-pre-pyloric-perforation-co-existing-with-sigmoid-volvulus-in-a-middle-aged-patient
#32
Mihir Patil, Pankaj Gharde
Sigmoid volvulus is a common cause of colonic obstruction worldwide and constitutes the majority of all cases of colonic volvulus. It is more prevalent in those who are older than 70 years. The sigmoid colon, an S-shaped portion of the large intestine, is susceptible to this condition due to its redundancy and mobile nature. Treatment involves endoscopic detorsion with sigmoidectomy. Laparoscopic surgery has been found to be useful in terms of reduced morbidity, blood loss, analgesics, and hospital stay; contrarily, surgical management has been found to be associated with reduced recurrence...
February 2024: Curēus
https://read.qxmd.com/read/38546641/anti-helicobacter-pylori-treatment-in-patients-with-gastric-cancer-after-radical-gastrectomy
#33
JOURNAL ARTICLE
Zhoukai Zhao, Ruopeng Zhang, Guoming Chen, Man Nie, Feiyang Zhang, Xiaojiang Chen, Jun Lin, Zewei Chen, Feizhi Lin, Chengzhi Wei, Ziqi Zheng, Shenghang Ruan, Bowen Huang, Yingbo Chen, Runcong Nie
IMPORTANCE: Whether anti-Helicobacter pylori treatment can provide survival benefits for patients with gastric cancer who are diagnosed with H pylori infection is an area with limited research. OBJECTIVE: To explore the potential survival benefits of anti-H pylori treatment after radical gastrectomy in patients with gastric cancer and presurgical confirmation of H pylori infection. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study was conducted using data from patients with gastric cancer treated between January 1, 2010, and December 31, 2018, and followed up for outcome ascertainment until May 19, 2021...
March 4, 2024: JAMA Network Open
https://read.qxmd.com/read/38544952/response-to-article-kaempferia-parviflora-extracellular-vesicle-loaded-with-clarithromycin-for-the-treatment-of-helicobacter-pylori-infection-letter
#34
JOURNAL ARTICLE
Putu Yuliandari, Masri Sembiring Maha, Novaria Sari Dewi Panjaitan
No abstract text is available yet for this article.
2024: International Journal of Nanomedicine
https://read.qxmd.com/read/38544338/a-natural-peptide-from-a-traditional-chinese-medicine-has-the-potential-to-treat-chronic-atrophic-gastritis-by-activating-gastric-stem-cells
#35
JOURNAL ARTICLE
Ke Li, Xiuying Ma, Zihao Li, Ya Liu, Guiyan Shen, Zecheng Luo, Dong Wang, Li Xia, Zhengting Wang, Ming Tian, Huijuan Liu, Funeng Geng, Baojie Li
Chronic atrophic gastritis (AG) is initiated mainly by Helicobacter pylori infection, which may progress to stomach cancer following the Correa's cascade. The current treatment regimen is H. pylori eradication, yet evidence is lacking that this treatment is effective on later stages of AG especially gastric gland atrophy. Here, using AG mouse model, patient samples, gastric organoids, and lineage tracing, this study unraveled gastric stem cell (GSC) defect as a crucial pathogenic factor in AG in mouse and human...
March 27, 2024: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
https://read.qxmd.com/read/38543480/minocycline-amoxicillin-based-bismuth-quadruple-therapy-for-helicobacter-pylori-eradication-a-pilot-study
#36
JOURNAL ARTICLE
Senlin You, Xiaoqiong Tang, Jiarui Zhou, Yalin Shen, Xiaona Song, Mohammed Benghezal, Barry J Marshall, Hong Tang, Hong Li
The common adverse effects and the complicated administration of tetracycline and metronidazole greatly affect the clinical application of the classical bismuth quadruple therapy (BQT) for Helicobacter pylori eradication. This pilot study aimed to evaluate the efficacy and safety of minocycline/amoxicillin-based BQT for H. pylori eradication. Firstly, consecutive H. pylori isolates collected at West China Hospital of Sichuan University between 2018 and 2021 were included for susceptibility testing of tetracycline and minocycline using E-test strips...
February 20, 2024: Microorganisms
https://read.qxmd.com/read/38542354/gastric-cancer-in-the-era-of-epigenetics
#37
REVIEW
Grigorios Christodoulidis, Konstantinos-Eleftherios Koumarelas, Marina-Nektaria Kouliou, Eleni Thodou, Maria Samara
Gastric cancer (GC) remains a significant contributor to cancer-related mortality. Novel high-throughput techniques have enlightened the epigenetic mechanisms governing gene-expression regulation. Epigenetic characteristics contribute to molecular taxonomy and give rise to cancer-specific epigenetic patterns. Helicobacter pylori (Hp) infection has an impact on aberrant DNA methylation either through its pathogenic CagA protein or by inducing chronic inflammation. The hypomethylation of specific repetitive elements generates an epigenetic field effect early in tumorigenesis...
March 16, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38542051/trends-of-early-helicobacter-pylori-uninfected-gastric-cancer-in-an-aging-regional-area
#38
JOURNAL ARTICLE
Hidehito Maeda, Fumisato Sasaki, Takayuki Ooi, Shohei Uehara, Hiroki Yano, Yoichi Sameshima, Yoshio Fukuda, Yuichiro Nasu, Yusuke Fujino, Koichiro Shigeta, Hiroshi Fujita, Akihito Tanaka, Shuji Kanmura, Akio Ido
Background/Objectives : We aimed to determine the trends over time and current status of early Helicobacter pylori -uninfected gastric cancer (HpUIGC) treatment in a region with an aging population. Methods : This retrospective, multi-center observational study was conducted at seven major general hospitals in Kagoshima Prefecture. From January 2009 to July 2022, 2091 patients who received endoscopic resection (ER) for early gastric cancer (EGC) were retrospectively enrolled, of which 35 were identified as early HpUIGC cases...
March 21, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38537343/an-all-in-one-therapeutic-platform-for-the-treatment-of-resistant-helicobacter-pylori-infection
#39
JOURNAL ARTICLE
Chao Sun, Jia Huang, Xiaoqian Guo, Chenli Zhang, Li Wei, Ka Ioi Wong, Ziyun Yang, Gang Zhao, Min Lu, Weiyan Yao
Helicobacter pylori (H. pylori) infection is a major cause of gastric diseases. Currently, bismuth-based quadruple therapy is widely adopted for eradicating H. pylori infection. However, this first-line strategy faces several challenges such as drug resistance, intestinal dysbacteriosis, and patients' poor compliance. To overcome these problems, an all-in-one therapeutic platform (CLA-Bi-ZnO2 @Lipo) that composed of liposomes loading clarithromycin (CLA), Bi, and ZnO2 hybrid nanoparticles was developed for eradicating multidrug-resistant (MDR) H...
March 21, 2024: Biomaterials
https://read.qxmd.com/read/38534715/equivalence-trial-of-the-non-bismuth-10-day-concomitant-and-14-day-hybrid-therapies-for-helicobacter-pylori-eradication-in-high-clarithromycin-resistance-areas
#40
JOURNAL ARTICLE
Sotirios D Georgopoulos, Elias Xirouchakis, Christos Liatsos, Pericles Apostolopoulos, Panagiotis Kasapidis, Beatriz Martinez-Gonzalez, Fotini Laoudi, Maria Stoupaki, Georgios Axiaris, Dionysios Sgouras, Andreas Mentis, Spyridon Michopoulos
Background and aim : We conducted an equivalence trial of quadruple non-bismuth "concomitant" and "hybrid" regimens for H. pylori eradication in a high clarithromycin resistance area. Methods : There were 321 treatment-naïve H. pylori -positive individuals in this multicenter clinical trial randomized to either the hybrid (esomeprazole 40 mg/bid, amoxicillin 1 g/bid for 7 days, then 7 days esomeprazole 40 mg/bid, amoxicillin 1 g/bid, clarithromycin 500 mg/bid, and metronidazole 500 mg/bid) or the concomitant regimen (all medications given concurrently bid for 10 days)...
March 20, 2024: Antibiotics
keyword
keyword
73246
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.